Pfizer India and Cipla Ltd on Friday announced an exclusive partnership under which Cipla will market and distribute select Pfizer brands in India, significantly enhancing their availability for patients nationwide.

Under the agreement, Cipla will have the exclusive rights to market, distribute and sell Pfizer’s cough syrups Corex DX and Corex LS, NSAID Dolonex, proton pump inhibitor Neksium, and oral antibiotic Dalacin C in India. Pfizer will continue to manufacture, source and supply these medicines to Cipla for the Indian market.

Meenakshi Nevatia, Country President, Pfizer India, said the partnership aligns with Pfizer’s focus on expanding patient access to its medicines, leveraging Cipla’s extensive distribution reach across the country.

Achin Gupta, Global Chief Operating Officer, Cipla Ltd, said the association supports Cipla’s strategy to strengthen its presence across key therapy areas and improve access to high-quality treatments, guided by the company’s purpose of “Caring for Life”.

Pfizer has been present in India for over 75 years. This marks the first partnership between Pfizer and Cipla in the Indian market and is aimed at combining Pfizer’s established product portfolio with Cipla’s deep market reach to serve patients across India more effectively.